Safety of routine childhood vaccinations: An epidemiological review

被引:19
作者
Chen R.T. [1 ]
Mootrey G. [1 ]
DeStefano F. [1 ]
机构
[1] Vaccine Safety/Devt. Branch, National Immunisation Program, Centers for Dis. Ctrl./Prevention, Atlanta
来源
Paediatric Drugs | 2000年 / 2卷 / 4期
关键词
Chronic Fatigue Syndrome; Aseptic Meningitis; Vaccine Safety; Oral Poliovirus Vaccine; Vaccine Adverse Event Reporting System;
D O I
10.2165/00128072-200002040-00004
中图分类号
学科分类号
摘要
Immunisations have been one of the most cost-effective public health interventions in human history. Despite remarkable progress, several challenges face immunisation programs worldwide. Paradoxically, despite vaccines' clear effectiveness in reducing risks of diseases that were previously widely prevalent and caused substantial morbidity and mortality, current vaccination policies have become increasingly controversial due to concerns about vaccine safety. Vaccines, like other pharmaceutical products, are not entirely risk-free. While most known adverse effects are minor and self-limited, some vaccines have been associated with very rare but serious adverse effects. Because such rare effects are often not evident until vaccines come into widespread use, ongoing surveillance programs to monitor vaccine safety are needed. Such monitoring will be essential if the public is to accept the increasing number of new vaccines made possible by biotechnology. The interpretation of data from vaccine safety research is complex and is associated with some uncertainty. Effectively communicating this uncertainty and continuing to improve understanding of rare risks and risk factors are essential for 'mature' immunisation programs to maintain public confidence in immunisations.
引用
收藏
页码:273 / 290
页数:17
相关论文
共 158 条
[1]  
(1993)
[2]  
Fenner F., Henderson D.A., Arita I., Et al., (1988)
[3]  
Progress toward global poliomyelitis eradication 1997-1998, MMWR Morb Mortal Wkly Rep, 48, 20, pp. 416-421, (1999)
[4]  
(1999)
[5]  
Chen R.T., Rastogi S.C., Mullen J.R., Et al., The vaccine adverse event reporting system (VAERS), Vaccine, 12, pp. 542-550, (1994)
[6]  
Kemp T., Pearce N., Fitzharris P., Et al., Is infant immunization a risk factor for childhood asthma or allergy?, Epidemiology, 8, pp. 678-680, (1997)
[7]  
Wakefield A.J., Murch S.H., Anthony A., Et al., Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and regressive developmental disorder in children, Lancet, 351, pp. 637-641, (1998)
[8]  
Classen D.C., Classen J.B., The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus, Infect Dis Clin Pract, 6, pp. 449-454, (1997)
[9]  
Gout O., Lyon-Caen O., Sclerose en plaques et vaccination contre le virus de l'hepatite B, Rev Neurol Paris, 154, pp. 205-207, (1998)
[10]  
Ellenberg S.S., Chen R.T., The complicated task of monitoring vaccine safety, Public Health Rep, 112, pp. 10-20, (1997)